Candidate biomarkers of CPI response in sarcoma patients include TIL density, presence of tertiary lymphoid structures, PD-1/PD-L1 expression and transcriptomic-based sarcoma immune classes39,55–57. This evidence concerns the gene PDCD1 and sarcoma.